Drugs / IDE574
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07540572 | Mar 2026 → Mar 2030 expected | castration-resistant prostate carcinoma, colorectal carcinoma, estrogen-receptor positive breast cancer, non-small cell lung carcinoma | IDEAYA Biosciences | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-03-18 | IDEAYA Biosciences | Results IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs ideayabio.com ↗
The KAT6/7 inhibitor IDE574 disrupts tumor lineage identity and drug tolerance to deliver robust antitumor activity in biomarker selected indications |
| 2025-12-10 | IDEAYA Biosciences | Regulatory IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers ideayabio.com ↗ |
All press releases naming this drug 3 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IDE574 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07540572 ↗ |
| Action | Inhibit | “small molecule inhibitor that co-targets” NCT07540572 ↗ |
| Modality | Small molecule | “IDE574 is a synthetically manufactured small molecule inhibitor” NCT07540572 ↗ |
| Target | KAT7 | “IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7.” NCT07540572 ↗ |